Synopsis
Synopsis
0
KDMF
0
VMF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Salmeterol
2. Serevent
3. Xinafoate, Salmeterol
1. 94749-08-3
2. Salmetedur
3. Arial
4. Gr 33343x Xinafoate
5. Salmeterol 1-hydroxy-2-naphthoate
6. Salmeterolo
7. Salmeterol (xinafoate)
8. 4-(1-hydroxy-2-((6-(4-phenylbutoxy)hexyl)amino)ethyl)-2-(hydroxymethyl)phenol 1-hydroxy-2-naphthoate
9. Gr 33343 G
10. 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol;1-hydroxynaphthalene-2-carboxylic Acid
11. Serevent Diskus
12. 6ew8q962a5
13. Gr-33343x
14. Gr-33343 G
15. Ncgc00094372-03
16. Asmerole
17. Betamican
18. Dilamax
19. Inaspir
20. Ultrabeta
21. Beglan
22. Dsstox_cid_25798
23. Dsstox_rid_81137
24. Dsstox_gsid_45798
25. Serevent Inhaler And Disks
26. Salmeterol Xinafoate [usan]
27. Smr000875207
28. Cas-94749-08-3
29. Unii-6ew8q962a5
30. Salmeterol Xinafoate [usan:usp]
31. Serevent (tn)
32. 4-[1-hydroxy-2-[[6-(4-phenylbutoxy)hexyl]amino]ethyl]-2-(hydroxymethyl)phenol 1-hydroxy-2-naphthoate
33. Salmeterol, 1-hydroxy-2-naphthoate
34. Mfcd00897708
35. Schembl18070
36. (+-)-4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol 1-hydroxy-2-naphthoate (salt)
37. Mls001332577
38. Mls001332578
39. Chebi:9012
40. Lipo-202
41. Chembl1082607
42. Dtxsid1045798
43. Salmeterol Xinafoate (jan/usp)
44. Hms2232i16
45. Hms3263k22
46. Hms3676p13
47. Hms3749i03
48. Hms3885j19
49. Salmeterol Xinafoate [jan]
50. Amy23373
51. Bcp04778
52. Salmeterol Xinafoate [vandf]
53. Tox21_111270
54. Tox21_501100
55. S4296
56. Salmeterol Xinafoate [mart.]
57. Salmeterol Xinafoate [usp-rs]
58. Salmeterol Xinafoate [who-dd]
59. Akos016004957
60. Tox21_111270_1
61. Ccg-270203
62. Cs-1527
63. Ks-1140
64. Lp01100
65. Ncgc00015938-05
66. Ncgc00094372-01
67. Ncgc00094372-02
68. Ncgc00094372-04
69. Ncgc00261785-01
70. 1,3-benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-, 1-hydroxy-2-naphthalenecarboxylate (salt)
71. Hy-17453
72. Salmeterol Xinafoate [ep Impurity]
73. Salmeterol Xinafoate [orange Book]
74. Bcp0726000003
75. Salmeterol Xinafoate [ep Monograph]
76. Advair Component Salmeterol Xinafoate
77. Db-057527
78. Salmeterol Xinafoate [usp Monograph]
79. Eu-0101100
80. Ft-0642283
81. Salmeterol Xinafoate, >=98% (hplc), Solid
82. D00687
83. Lipo-102 Component Salmeterol Xinafoate
84. R10007
85. Salmeterol 1-hydroxy-2-naphthoate [mi]
86. Salmeterol Xinafoate Component Of Advair
87. Advair Hfa Component Salmeterol Xinafoate
88. A916443
89. Sr-01000597359
90. Q-201697
91. Salmeterol Xinafoate Component Of Advair Hfa
92. Sr-01000597359-1
93. Airduo Respiclick Component Salmeterol Xinafoate
94. Q27264747
95. Salmeterol Xinafoate Component Of Airduo Respiclick
96. Salmeterol Xinafoate, European Pharmacopoeia (ep) Reference Standard
97. Salmeterol Xinafoate, United States Pharmacopeia (usp) Reference Standard
98. Salmeterol Xinafoate For System Suitability, European Pharmacopoeia (ep) Reference Standard
99. Salmeterol Xinafoate, Pharmaceutical Secondary Standards; Certified Reference Material
100. (+/-)-4-hydroxy-.alpha.(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-.alpha.,.alpha.'-diol 1-hydroxy-2-naphthoate
101. 1,3-benzenedimethanol, 4-hydroxy-.alpha.(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+/-)-, 1-hydroxy-2-naphthalenecarboxylate
102. 4-(1-hydroxy-2-(6-(4-phenylbutoxy)hexylamino)ethyl)-2-(hydroxymethyl)phenol 1-hydroxy-2-naphthoate
103. 4-hydroxy-?1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol 1-hydroxy-2-naphthalenecarboxylic Acid Salt
Molecular Weight | 603.7 g/mol |
---|---|
Molecular Formula | C36H45NO7 |
Hydrogen Bond Donor Count | 6 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 17 |
Exact Mass | 603.31960277 g/mol |
Monoisotopic Mass | 603.31960277 g/mol |
Topological Polar Surface Area | 140 Ų |
Heavy Atom Count | 44 |
Formal Charge | 0 |
Complexity | 629 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Bronchodilator Agents
Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)
Adrenergic beta-2 Receptor Agonists
Compounds bind to and activate ADRENERGIC BETA-2 RECEPTORS. (See all compounds classified as Adrenergic beta-2 Receptor Agonists.)
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-08-12
Pay. Date : 2015-05-20
DMF Number : 23914
Submission : 2010-06-23
Status : Active
Type : II
Certificate Number : R1-CEP 2007-127 - Rev 00
Issue Date : 2014-06-16
Type : Chemical
Substance Number : 1765
Status : Valid
NDC Package Code : 64567-0007
Start Marketing Date : 2008-03-27
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Available Reg Filing : CN |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26863
Submission : 2013-02-04
Status : Active
Type : II
Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.
Certificate Number : CEP 2006-226 - Rev 03
Issue Date : 2024-03-05
Type : Chemical
Substance Number : 1765
Status : Valid
Date of Issue : 2022-06-13
Valid Till : 2025-07-02
Written Confirmation Number : WC-0155
Address of the Firm :
NDC Package Code : 66412-0768
Start Marketing Date : 2023-09-25
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
Certificate Number : R0-CEP 2018-168 - Rev 00
Issue Date : 2020-06-12
Type : Chemical
Substance Number : 1765
Status : Valid
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Certificate Number : CEP 2018-044 - Rev 04
Issue Date : 2024-02-01
Type : Chemical
Substance Number : 1765
Status : Valid
Date of Issue : 2022-09-16
Valid Till : 2025-07-05
Written Confirmation Number : WC-0009
Address of the Firm :
Aarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-07-05
Pay. Date : 2015-01-05
DMF Number : 22054
Submission : 2008-10-03
Status : Active
Type : II
Certificate Number : R1-CEP 2008-239 - Rev 04
Issue Date : 2022-10-14
Type : Chemical
Substance Number : 1765
Status : Valid
Registration Number : 227MF10240
Registrant's Address : 71, UDYOG KSHETRA, ULND-GOREGAON LINK ROAD, MULUND (W), MUMBAI 400080, INDIA
Initial Date of Registration : 2015-09-29
Latest Date of Registration : --
Date of Issue : 2023-01-06
Valid Till : 2025-07-29
Written Confirmation Number : WC-0099
Address of the Firm :
NDC Package Code : 15308-1021
Start Marketing Date : 2016-01-21
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (5kg/5kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-12-14
Pay. Date : 2015-12-07
DMF Number : 22973
Submission : 2009-07-22
Status : Active
Type : II
Certificate Number : CEP 2011-277 - Rev 03
Issue Date : 2023-09-12
Type : Chemical
Substance Number : 1765
Status : Valid
Date of Issue : 2022-07-28
Valid Till : 2025-06-16
Written Confirmation Number : WC-0036
Address of the Firm :
NDC Package Code : 58032-0143
Start Marketing Date : 2017-12-13
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?